Duavee: a tissue-selective estrogen complex for menopausal symptoms and prevention of osteoporosis.
Loading...
Date
2015-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Post-menopausal women suffer from a plethora of problems like vasomotor
symptoms, vulvovaginal atrophy (VVA), bone loss, and all this can be attributed to
estrogen deficiency. The conventional treatment till date for these hormone deficient
manifestations have been estrogen replacement therapy in hysterectomized female or
a combination of estrogen and progesterone therapy in women with an intact uterus.
The reason for adding progesterone is to protect the endometrium from estrogenic
stimulation. The drawback with the combination therapy was irregular vaginal
bleeding and breast discomfort, which led to the discontinuation of this therapy.
The United States Food and Drug Administration, has recently approved a novel
tissue selective estrogen complex comprising of conjugated estrogen (0.45 mg) and a
selective estrogen receptor modulator, bazedoxifene (BZA) (20 mg) for the treatment
of moderate to severe vasomotor symptoms and prevention of osteoporosis in nonhysterectomized
post-menopausal women. This combination retains the benefits of
estrogen on vasomotor symptoms, VVA and bone density along with the protective
effect of BZA on endometrium and breast tissue. The results of clinical trials have
been promising but what still needs to be evaluated is the long term safety of this
pair on venous thromboembolism, stroke, and breast cancer.
Description
Keywords
Bazedoxifene, Conjugated estrogen, Menopause, Osteoporosis
Citation
Tikoo Deepika, Gupta Meenakshi. Duavee: a tissue-selective estrogen complex for menopausal symptoms and prevention of osteoporosis. International Journal of Basic & Clinical Pharmacology. 2015 Mar-Apr; 4(2): 391-396.